

Kim Reynolds GOVERNOR

Adam Gregg LT. GOVERNOR

> Kelly Garcia DIRECTOR

December 14th, 2022

# COVID-19 Therapeutics Information Brief

Changes to the document from the previous version are highlighted in yellow.

### **IMPORTANT/NEW COVID-19 Therapeutics Information**

- Therapeutics Ordering Schedule
- COVID-19 Therapeutics Information Brief Schedule
- HPOP Updates
- Allocations for Pre-Exposure Prophylaxis Treatment and Oral Antivirals
- Expiration Dating Extension Reminder
- Therapeutic Reporting Cadence
- COVID-19 Therapeutics Information Resources

## **Therapeutics Ordering Schedule**

Effective January 2023 Therapeutic Ordering will transition to a monthly cadence. The planned schedule for orders are as follows:

Survey Sent	Survey Closed	Order Placed
1/17/2022	1/18/2022	1/19/2022
2/13/2022	2/14/2022	20/15/2022

- Iowa HHS encourages entities who do receive allocations of therapeutic products to notify and work with prescribers and LPHAs on the availability of therapeutic products in the community.
- The Department of Health and Human Services has released a COVID-19 Therapeutics locator.

### **COVID-19 Therapeutics Information Brief Schedule**

Effective immediately COVID-19 Therapeutic Information Briefs will move to an as needed basis.

- You may contact the COVID-19 Therapeutics Call Center at any time
  - o Phone: (515) 281-7317
  - o Email: C19Therapeutics@idph.iowa.gov

#### **HPOP Updates**

If the HPOP listed pharmacy/provider license number has a 2022 expiration date in HPOP please email the updated license expiration date and any changes to the license number to <a href="mailto:c19therapeutics@idph.iowa.gov">c19therapeutics@idph.iowa.gov</a> or call 515-281-7317.

## Allocations Thresholds for Pre-Exposure Prophylaxis Treatment and Antivirals

Iowa Statewide Allocations Threshold Remaining for the week Monday, December 12th, 2022 - Sunday December 18th, 2022				
Oral AVs			PrEP	
Mulnupiravir (Lagevrio)	Paxlovid	Renal Paxlovid	EVUSHELD	
158 courses	880 courses	80 courses	1812 doses (monthly allocation)	

### **Expiration Dating Extension Reminder**

Recent shelf-life extensions have been issued for several products. Before wasting any product, be sure to check for expiration date extensions by using one or more of the following resources:

- FDA COVID-19 Therapeutics Extensions
- Call: 515-281-7317
- Email: C19Therapeutics@idph.iowa.gov

Select lots of Evusheld will have had expiration dates extended from 18 to 30 months. Details may be found HERE.

Select lots of Paxlovid will have had expiration dates extended from 12 to 18 months. Details may be found <u>HERE</u>.

## **Therapeutic Reporting Cadence**

Sites receiving monoclonal antibodies, pre-exposure prophylaxis treatment, or oral antivirals MUST comply with federal reporting requirements.

Failure to comply with reporting requirements may result in the loss of COVID-19 therapeutic providers status and removal of COVID-19 therapeutic products. **Reporting requirements are as follows:** 

- For legacy mAbs (Bebtelovimab, Regeneron, Bam/ete, Sotrovimab): Report on-hand data once per week in HPOP.
  - Reporting should be completed by 11:59 pm on Thursday
- (Evusheld, Paxlovid, and Molnupiravir): Report on-hand and usage data twice per week in HPoP.
  - Reporting should be completed by 11:59 pm on MONDAY and THURSDAY
  - Internet Explorer is NOT supported, please use Chrome, Firefox, Edge or Safari
- Reporting should include product doses utilized since the last report date
- Reporting IS NOT a cumulative total of all doses utilized to date
- Please contact <u>C19therapeutics@idph.iowa.gov</u> for assistance with HPOP

Healthcare providers should ensure reporting of the correct Paxlovid or Renal Paxlovid product. Paxlovid (renal) was renamed as Renal Paxlovid and the display order was changed to separate the Paxlovid products.

#### **COVID-19 Therapeutics Information Resources**

- COVID-19 Therapeutics Call Center: 515-281-7317.
- **COVID-19 Therapeutics Email**: Therapeutic questions from healthcare providers can be emailed to: <u>C19Therapeutics@idph.iowa.gov</u>
- <u>COVID-19 Therapeutics Table</u>: IDPH has developed a table of therapeutic products available for the treatment or prevention of COVID-19.
- Outpatient Therapeutics Decision Aid
- Side-by-Side Overview Outpatient Therapeutics
- NIH COVID-19 Treatment Guidelines